2,596 Shares in IQVIA Holdings Inc. $IQV Bought by Continuum Advisory LLC

Continuum Advisory LLC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,596 shares of the medical research company’s stock, valued at approximately $502,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of IQV. Korea Investment CORP bought a new position in shares of IQVIA during the second quarter worth approximately $13,918,000. Deutsche Bank AG acquired a new position in IQVIA in the 2nd quarter valued at $143,074,000. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter worth $2,811,292,000. Focus Partners Advisor Solutions LLC bought a new position in IQVIA during the 2nd quarter worth $976,000. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of IQVIA during the second quarter worth $1,552,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Down 1.6%

Shares of IQV opened at $267.34 on Friday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $271.80. The firm has a market cap of $44.00 billion, a price-to-earnings ratio of 33.17, a PEG ratio of 2.32 and a beta of 1.18. The business’s fifty day moving average is $230.54 and its 200-day moving average is $192.66.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.IQVIA’s revenue was up 8.7% compared to the same quarter last year. During the same period last year, the firm posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on IQV shares. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Finally, TD Cowen raised their price objective on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $243.62.

Insider Buying and Selling at IQVIA

In related news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider owned 10,890 shares of the company’s stock, valued at $2,845,883.70. This represents a 19.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,581 shares of company stock worth $3,796,021 over the last 90 days. 1.70% of the stock is owned by corporate insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.